# Korea Post Marketing Surveillance (PMS) Study of Talzenna®

> **NCT04982848** · — · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 600 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Talzenna

## Key facts

- **NCT ID:** NCT04982848
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-06-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982848, "Korea Post Marketing Surveillance (PMS) Study of Talzenna®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04982848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*